The Johnson & Johnson, or Janssen, COVID-19 vaccine is a single-dose vaccine to avoid COVID-19. This Snapshot feature addresses potential side effects and the controversies surrounding the recent blood clotting incidents.
The Johnson & Johnson COVID-19 vaccine, also known as Ad26.COV2.S, originated by Janssen Pharmaceuticals of Johnson & Johnson.
This is a single-dose vaccine, which differentiates it from two-dose COVID-19 vaccines, like the ones from Pfizer and Moderna.
In early 2021, the Food and Drug Administration (FDA)Trusted Source and, after a recommendation from the European Medicines Agency (EMA), the European Commission issued emergency and conditional authorization for the Johnson & Johnson vaccine for individuals aged 18 years and older. The vaccine has been approved for emergency use in 40 countries.
However, the FDA recommended a pause in the vaccine’s use, as a precautionary measure following a tiny number of rare blood clot incidents. As well, Johnson & Johnson delayed the distribution of the vaccine in Europe as the EMA conducted its own review.
On April 20, the company announced it would resume distribution of its vaccine in europe but with a safety warning, following the EMA figured the vaccine’s benefits continue steadily to outweigh its risks.
After halting vaccination in america a couple weeks ago, the FDA and the CDC recently recommendedTrusted Source that vaccinations resume. They noted, however, that women beneath the age of 50 should be aware of the risk of rare blood clots.
Moreover, both agencies want women to learn that alternative COVID-19 vaccines are available, for which there are no reports of rare blood clots.
The World Health Organization (WHO)Trusted Source has explained that, although it continues to monitor the safety responses from regulatory agencies, the vaccine is effective and safe against the extreme risks of COVID-19.